Bronchoalveolar lavage as a research tool

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 5, 2007, Pages 561-573

  Rose, Anthony S ^a   Knox, Kenneth S ^a,b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acellular; Bronchoalveolar lavage fluid; Cytometry; Immunology; Safety

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DIAGNOSTIC PROCEDURE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; LUNG ALVEOLUS CELL; LUNG DISEASE; LUNG LAVAGE; LYMPHOCYTE; PATHOGENICITY; PRIORITY JOURNAL; RESEARCH; RESEARCH SUBJECT; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT MUCOSA; SAFETY; TECHNOLOGY; THERAPY EFFECT; TREATMENT PLANNING;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTES; MACROPHAGES, ALVEOLAR; PULMONARY SURFACTANTS; RESEARCH; SAFETY; TECHNOLOGY, MEDICAL;

EID: 35648964221     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991528     Document Type: Article

References (136)

1. Baughman RP. The uncertainties of bronchoalveolar lavage. Eur Respir J 1997;10:1940-1942
2. Costabel U. Atlas of Bronchoalveolar Lavage. Philadelphia: Chapman & Hall Medical; 1998:91
3. Reynolds HY. Use of bronchoalveolar lavage in humans: past necessity and future imperative. Lung 2000;178:271-293
4. Rottoli P, Bargagli E. Is bronchoalveolar lavage obsolete in the diagnosis of interstitial lung disease? Curr Opin Pulm Med 2003;9:418-425
5. Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003;22:239-244
6. Ouellette DR. The safety of bronchoscopy in a pulmonary fellowship program. Chest 2006;130:1185-1190
7. Hart R, Classen M. Complications of diagnostic gastrointestinal endoscopy. Endoscopy 1990;22:229-233
8. Pingleton SK, Harrison GF, Stechschulte DJ, et al. Effect of location, pH, and temperature of instillate in bronchoalveolar lavage in normal volunteers. Am Rev Respir Dis 1983; 128:1035-1037
9. Strumpf IJ, Feld MK, Cornelius MJ, Keogh BA, Crystal RG. Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease. Chest 1981;80:268-271
10. Djukanovic R, Wilson JW, Lai CK, Holgate ST, Howarth PH. The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am Rev Respir Dis 1991;143(4 Pt 1):772-777
11. Hattotuwa K, Gamble EA, O'Shaughnessy T, Jeffery PK, Barnes NC. Safety of bronchoscopy, biopsy, and BAL in research patients with COPD. Chest 2002;122:1909-1912
12. Stanley MWH-S, Michelle J, Iber C. Bronchoalveolar Lavage. New York: Igaku-Shoin; 1991:240
13. Huang YC, Bassett MA, Levin D, Montilla T, Ghio AJ. Acute phase reaction in healthy volunteers after bronchoscopy with lavage. Chest 2006;129:1565-1569
14. Elston WJ, Whittaker AJ, Khan LN, et al. Safety of research bronchoscopy, biopsy and bronchoalveolar lavage in asthma. Eur Respir J 2004;24:375-377
15. Van Vyve T, Chanez P, Bousquet J, et al. Safety of bronchoalveolar lavage and bronchial biopsies in patients with asthma of variable severity. Am Rev Respir Dis 1992; 146:116-121
16. Busse WW, Wanner A, Adams K, et al. Investigative bronchoprovocation and bronchoscopy in airway diseases. Am J Respir Crit Care Med 2005;172:807-816
17. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 1999;14:245-248
18. Rennard SI, Ghafouri M, Thompson AB, et al. Fractional processing of sequential bronchoalveolar lavage to separate bronchial and alveolar samples. Am Rev Respir Dis 1990; 141:208-217
19. Lam S, Leriche JC, Kijek K, Phillips D. Effect of bronchial lavage volume on cellular and protein recovery. Chest 1985;88:856-859
20. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990;141(5 Pt 2):S169-S202
21. Jones KP, Edwards JH, Reynolds SP, Peters TJ, Davies BH. A comparison of albumin and urea as reference markers in bronchoalveolar lavage fluid from patients with interstitial lung disease. Eur Respir J 1990;3:152-156
22. Dargaville PA, South M, Vervaart P, McDougall PN. Validity of markers of dilution in small volume lung lavage. Am J Respir Crit Care Med 1999;160:778-784
23. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-538
24. Marcy TW, Merrill WW, Rankin JA, Reynolds HY. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis 1987;135:1276-1280
25. Ward C, Duddridge M, Fenwick J, et al. The origin of water and urea sampled at bronchoalveolar lavage in asthmatic and control subjects. Am Rev Respir Dis 1992; 146:444-447
26. Ishizaka A, Watanabe M, Yamashita T, et al. New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome. Crit Care Med 2001; 29:896-898
27. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999;27:304-312
28. Yamazaki K, Ogura S, Ishizaka A, Oh-hara T, Nishimura M. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med 2003;168:1304-1307
29. Sasabayashi M, Yamazaki Y, Tsushima K, Hatayama O, Okabe T. Usefulness of bronchoscopic microsampling to detect the pathogenic bacteria of respiratory infection. Chest 2007;131:474-479
30. Larsson K, Tornling G, Gavhed D, Muller-Suur C, Palmberg L. Inhalation of cold air increases the number of inflammatory cells in the lungs in healthy subjects. Eur Respir J 1998;12:825-830
31. Reynolds HY. Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am J Respir Crit Care Med 2005;171:98-102
32. Carre PC, Mortenson RL, King TE Jr, et al. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis: a potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 1991;88:1802-1810
33. Hunninghake GW, Gadek JE, Fales HM, Crystal RG. Human alveolar macrophage-derived chemotactic factor for neutrophils: stimuli and partial characterization. J Clin Invest 1980;66:473-483
34. Merrill WW, Naegel GP, Matthay RA, Reynolds HY. Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization. J Clin Invest 1980;65:268-276
35. Holt PG, Oliver J, Bilyk N, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993;177:397-407
36. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol 2004;31: 3-7
37. Lehnert BE, Valdez YE, Sebring RJ, et al. Airway intraluminal macrophages: evidence of origin and comparisons to alveolar macrophages. Am J Respir Cell Mol Biol 1990;3: 377-391
38. Lofdahl JM, Wahlstrom J, Skold CM. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and nonsmokers. Clin Exp Immunol 2006;145:428-437
39. Wu HM, Jin M, Marsh CB. Toward functional proteomics of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2005;288:L585-L595
40. Frank JA, Wray CM, McAuley DF, Schwendener R, Matthay MA. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291:L1191-L1198
41. Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003;21: 421-428
42. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802
43. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 2006;194:1375-1384
44. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003;81:289-296
45. Berenson CS, Wrona CT, Grove LJ, et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 174:31-40
46. De Brauwer EI, Jacobs JA, Nieman F, et al. Cytocentrifugation conditions affecting the differential cell count in bronchoalveolar lavage fluid. Anal Quant Cytol Histol 2000;22:416-422
47. Mordelet-Dambrine M, Arnoux A, Stanislas-Leguern G et al. Processing of lung lavage fluid causes variability in bronchoalveolar cell count. Am Rev Respir Dis 1984;130: 305-306
48. Saltini C, Hance AJ, Ferrans VJ, et al. Accurate quantification of cells recovered by bronchoalveolar lavage. Am Rev Respir Dis 1984;130:650-658
49. Curtis JL. Cell-mediated adaptive immune defense of the lungs. Proc Am Thorac Soc 2005;2:412-416
50. Lehmann C, Wilkening A, Leiber D, et al. Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system. Anat Rec 2001;264:229-236
51. Tsao TC, Chen CH, Hong JH, et al. Shifts of T4/T8 T lymphocytes from BAL fluid and peripheral blood by clinical grade in patients with pulmonary tuberculosis. Chest 2002;122:1285-1291
52. Hodge G, Hodge S, Reynolds PN, Holmes M. Compartmentalization of intracellular proinflammatory cytokines in bronchial intraepithelial T cells of stable lung transplant patients. Clin Exp Immunol 2006;145:413-419
53. Twigg HL, Soliman DM, Day RB, et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999;159(5 Pt 1):1439-1444
54. Twigg HL III, Spain BA, Soliman DM, et al. Production of interferon-gamma by lung lymphocytes in HIV-infected individuals. Am J Physiol 1999;276(2 Pt 1):L256-L262
55. Brenchley JM, Schacker TW, Ruff LE, et al. CD4 + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200: 749-759
56. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770
57. Ely KH, Cookenham T, Roberts AD, Woodland DL. Memory T cell populations in the lung airways are maintained by continual recruitment. J Immunol 2006; 176:537-543
58. Delude RL. Flow cytometry. Crit Care Med 2005;33 (Suppl 12):S426-S428
59. Kaleem Z. Flow cytometric analysis of lymphomas: current status and usefulness. Arch Pathol Lab Med 2006;130: 1850-1858
60. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78
61. Morgan E, Varro R, Sepulveda H, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 2004;110:252-266
62. Kern F, LiPira G, Gratama JW, Manca F, Roederer M. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 2005;26:477-484
63. Barry SM, Condez A, Johnson MA, Janossy G. Determination of bronchoalveolar lavage leukocyte populations by flow cytometry in patients investigated for respiratory disease. Cytometry 2002;50:291-297
64. Roberts SD, Kohli LL, Wood KL, Wilkes DS, Knox KS. CD4 + CD28-T cells are expanded in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:13-19
65. Skold CM, Eklund A, Hallden G, Hed J. Autofluorescence in human alveolar macrophages from smokers: relation to cell surface markers and phagocytosis. Exp Lung Res 1989; 15:823-835
66. Smith PA, Kohli LM, Wood KL, et al. Cytometric analysis of BAL T cells labeled with a standardized antibody cocktail correlates with immunohistochemical staining. Cytometry 2006;70:170-178
67. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004;10:927-934
68. Ersch J, Tschernig T, Stallmach T. Frequency and potential cause of bronchus-associated lymphoid tissue in fetal lungs. Pediatr Allergy Immunol 2005;16:295-298
69. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006;116:3183-3194
70. Suda T, Chida K, Hayakawa H, et al. Development of bronchus-associated lymphoid tissue in chronic hypersensitivity pneumonitis. Chest 1999;115:357-363
71. Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 2000;68:1-8
72. Hiller AS, Tschernig T, Kleemann WJ, Pabst R. Bronchus-associated lymphoid tissue (BALT) and larynx-associated lymphoid tissue (LALT) are found at different frequencies in children, adolescents and adults. Scand J Immunol 1998; 47:159-162
73. Sue-Chu M, Karjalainen EM, Altraja A, et al. Lymphoid aggregates in endobronchial biopsies from young elite cross-country skiers. Am J Respir Crit Care Med 1998;158:597-601
74. Bienenstock J, McDermott MR. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 2005;206:22-31
75. Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2006;117(Suppl 2):S450-S456
76. Kariyawasam HH, Robinson DS. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med 2006;27:117-127
77. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils, I: Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002; 169:6452-6458
78. Liu LY, Jarjour NN, Busse WW, Kelly EA. Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge. J Allergy Clin Immunol 2003;112:556-562
79. Das AM, Vaddi KG, Solomon KA, et al. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation. J Pharmacol Exp Ther 2006;318:411-417
80. Julius P, Hochheim D, Boser K, et al. Interleukin-5 receptors on human lung eosinophils after segmental allergen challenge. Clin Exp Allergy 2004;34:1064-1070
81. Hogaboam CM, Carpenter KJ, Schuh JM, et al. The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary disease. Pharmacol Ther 2005;107:314-328
82. Luijk B, Lindemans CA, Kanters D, et al. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J Allergy Clin Immunol 2005;115:997-1003
83. Woodman L, Sutcliffe A, Kaur D, et al. Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects. Chest 2006;130:371-378
84. Akbari O, Faul JL, Hoyte EG, et al. CD4 + invariant T-cell-receptor + natural killer T cells in bronchial asthma. N Engl J Med 2006;354:1117-1129
85. Jain P, Sandur S, Meli Y, et al. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004;125:712-722
86. Hage CA, Davis TE, Egan L, et al. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay. Respir Med 2007; 101:43-47
87. Wheat LJ, Garringer T, Brizendine E, Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory. Diagn Microbiol Infect Dis 2002;43:29-37
88. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004;42:5517-5522
89. Kralovic SM, Rhodes JC. Utility of routine testing of bronchoalveolar lavage fluid for cryptococcal antigen. J Clin Microbiol 1998;36:3088-3089
90. Baughman RP, Rhodes JC, Dohn MN, Henderson H, Frame PT. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. Am Rev Respir Dis 1992;145:1226-1229
91. Malabonga VM, Basti J, Kamholz SL. Utility of bronchoscopic sampling techniques for cryptococcal disease in AIDS. Chest 1991;99:370-372
92. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 2007;45:676-677
93. Hayden RT, Uhl JR, Qian X, et al. Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture. J Clin Microbiol 2001;39:2618-2626
94. Wattiez R, Falmagne P. Proteomics of bronchoalveolar lavage fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005;815:169-178
95. Magi B, Bargagli E, Bini L, Rottoli P. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 2006;6: 6354-6369
96. Hirsch J, Hansen KC, Burlingame AL, Matthay MA. Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1-L23
97. Bowler RP, Ellison MC, Reisdorph N. Proteomics in pulmonary medicine. Chest 2006;130:567-574
98. Chiu LM, Amsden GW. Intrapulmonary pharmacokinetics of antibacterial agents: implications for therapeutics. Am J Respir Med 2002;1:201-209
99. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004;125:965-973
100. Conte JE Jr, Golden JA, McIver M, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 2006;28:114-121
101. Conte JE Jr, Golden JA, Kelley MG, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005;26:449-456
102. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of rigecycline. Int J Antimicrob Agents 2005;25:523-529
103. Creuwels LA, van Golde LM, Haagsman HP. The pulmonary surfactant system: biochemical and clinical aspects. Lung 1997;175:1-39
104. Rooney SA. The surfactant system and lung phospholipid biochemistry. Am Rev Respir Dis 1985;131:439-460
105. Wright JR, Youmans DC. Pulmonary surfactant protein A stimulates Chemotaxis of alveolar macrophage. Am J Physiol 1993;264(4 Pt 1):L338-L344
106. Juers JA, Rogers RM, McCurdy JB, Cook WW. Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material. J Clin Invest 1976;58:271-275
107. van Iwaarden F, Weimers B, Verhoef J, Haagsman HP, van Golde LM. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990;2:91-98
108. Weissbach S, Neuendank A, Pettersson M, Schaberg T, Pison U. Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages. Am J Physiol 1994;267(6 Pt 1):L660-L666
109. Ansfield MJ, Benson BJ. Identification of the immunosuppressive components of canine pulmonary surface active material. J Immunol 1980;125:1093-1098
110. Wilsher ML, Hughes DA, Haslam PL. Immunoregulatory properties of pulmonary surfactant: influence of variations in the phospholipid profile. Clin Exp Immunol 1988;73:117-122
111. Wilsher ML, Hughes DA, Haslam PL. Immunoregulatory properties of pulmonary surfactant: effect of lung lining fluid on proliferation of human blood lymphocytes. Thorax 1988; 43:354-359
112. Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am Rev Respir Dis 1988; 138:990-998
113. Gunther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153:176-184
114. Hite RD, Seeds MC, Bowton DL, et al. Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction. Am J Physiol Lung Cell Mol Physiol 2005;288:L610-L617
115. Erpenbeck VJ, Schmidt R, Gunther A, Krug N, Hohlfeld JM. Surfactant protein levels in bronchoalveolar lavage after segmental allergen challenge in patients with asthma. Allergy 2006;61:598-604
116. Gunther A, Schmidt R, Nix F, et al. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J 1999;14:565-573
117. Griese M, Essl R, Schmidt R, et al. Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. Respir Res 2005;6:133
118. Daimon T, Tajima S, Oshikawa K, et al. KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia. Intern Med 2005;44:811-817
119. Kunitake R, Kuwano K, Yoshida K, et al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration 2001;68: 488-495
120. Xing JC, Chen WH, Han WH, et al. Changes of tumor necrosis factor, surfactant protein A, and phospholipids in bronchoalveolar lavage fluid in the development and progression of coal workers' pneumoconiosis. Biomed Environ Sci 2006;19:124-129
121. Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1998;1408:334-345
122. Takahashi H, Sano H, Chiba H, Kuroki Y. Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases. Curr Pharm Des 2006;12:589-598
123. Twigg HL III. Humoral immune defense (antibodies): recent advances. Proc Am Thorac Soc 2005;2:417-421
124. Merrill WW, Naegel GP, Olchowski JJ, Reynolds HY. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects: quantitation and comparison with immunoglobulins A and E. Am Rev Respir Dis 1985;131: 584-587
125. Reynolds HY, Merrill WM, Amento EP, Naegel GP. Immunoglobulin A in secretions from the lower human respiratory tract. Adv Exp Med Biol 1978;107:553-564
126. Holter JF, Weiland JE, Pacht ER, Gadek JE, Davis WB. Protein permeability in the adult respiratory distress syndrome: loss of size selectivity of the alveolar epithelium. J Clin Invest 1986;78:1513-1522
127. Hol BE, van de Graaf EA, Out TA, Hische EA, Jansen HM. IgM in the airways of asthma patients. Int Arch Allergy Appl Immunol 1991;96:12-18
128. Reynolds SP, Edwards JH, Jones KP, Davies BH. Immunoglobulin and antibody levels in bronchoalveolar lavage fluid from symptomatic and asymptomatic pigeon breeders. Clin Exp Immunol 1991;86:278-285
129. Wilson DR, Merrett TG, Varga EM, et al. Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med 2002;165:22-26
130. Bergmann M, Jonasson S, Klause N, et al. Analysis of immunoglobulins in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997;14:139-145
131. Out TA, van de Graaf EA, van den Berg NJ, Jansen HM. IgG subclasses in bronchoalveolar lavage fluid from patients with asthma. Scand J Immunol 1991;33:719-727
132. Qyarfordt I, Riise GC, Andersson BA, Larsson S. IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations. Thorax 2001;56:445-449
133. Qyarfordt I, Riise GC, Larsson S, et al. Immunological findings in blood and bronchoalveolar lavage fluid in chronic bronchitis patients with recurrent infectious exacerbations. Eur Respir J 1998;11:46-54
134. Fahy RJ, Diaz PT, Hart J, Wewers MD. BAL and serum IgG levels in healthy asymptomatic HIV-infected patients. Chest 2001;119:196-203
135. Gordon SB, Miller DE, Day RB, et al. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults. J Infect Dis 2003;188:666-670
136. Armbruster C, Krugluger W, Huber M, Stephan K. Immunoglobulin G Fc(gamma) receptor expression on polymorphonuclear cells in bronchoalveolar lavage fluid of HIV-infected and HIV-seronegative patients with bacterial pneumonia. Clin Chem Lab Med 2004;42:192-197